Positive Impact

01424 851 375

Dry Eye Mask for Soothing Comfort and Circulation

iflo USB heated eye mask


The use of heat is a well-established and important adjunct therapy in the management of meibomian gland dysfunction. As an Eye Care Professional your challenge is to deliver this therapy to your patients effectively and safely.

iFlo™ USB Heating Eye Compress gives you this reassurance and convenience to your patients.

iFlo™ USB Heating Eye Compress

iFlo™ USB Heating Eye Compress is a smart eye mask designed to provide heating comfort to the eyes. It can relieve eye fatigue and discomfort caused by dry eye or other eye problems. It can also accelerate the blood circulation around the eye to improve black eye circle conditions. There is a removable sheet on the eye mask for the user to clean and keep hygiene.

Benefits of
iFlo™ USB Heating Eye Compress

Eye relief

Relieves eye fatigue and discomfort, including dry eye and MGD.

Smart design for heating and comfort

It works by using the USB cable, connected to a power bank, computer, or any other power source to heat the mask for 12 minutes before automatically turning off.

Improved eye circulation

Enhances blood circulation, targeting black eye circle conditions.

Interested in using iFlo™ USB Heating Eye Compress in your practice?

Contact us to find out more about iFlo™ USB Heating Eye Compress and to order.

T: 01424 851 375

Read the news on
Positive Impact

Webinar: The Use of Heat in Managing MGD

Join Nick Atkins in this CPD webinar as he explores effective heat delivery options for managing MGD. Gain insights into both in-practice and at-home solutions to enhance your practice’s MGD management strategies.

Learn More
Two choices with easy empirical fitting

Positive Impact (PI) has launched two new contact lenses in the UK, Alexa high resolution AR, offering a…

Learn More
Our Annual Christmas Food Donation

In the true spirit of the season, we are thrilled to share a heartwarming tradition that has become…

Learn More


* Data was collected from a population of 22 eyes (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland
dysfunction. Additional inclusion/exclusion criteria were applied. More information can be found at ClinicalTrials.gov